It is generally underappreciated that the highly-transformed (high-grade) lymphomas such as DLBCL can undergo cell-signaling reprogramming due to additional mutations of BCR and members of its down-stream signaling pathways, including evidence of development of resistance to the previously applied targeted therapy (8). The gene discussed is BCR; the disease is lymphoma.